{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-090129","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.657551+00:00","generated_at":"2026-05-17T06:03:46.992122+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Oruka raises $180M; ORKA-001 Phase 1 shows ~100-day half-life, supports annual dosing","bullets":["Private placement gross proceeds ~$180M; issued 10.9M shares at $15.00 and pre-funded warrants for 1.07M shares.","ORKA-001 half-life ~100 days (>3x risankizumab), PK supports potential once-yearly maintenance dosing.","Phase 1 showed complete STAT3 inhibition through 24 weeks; no severe TEAEs; safety consistent with IL-23 class.","EVERLAST-A Phase 2a enrollment ongoing, data expected 2H 2026; EVERLAST-B Phase 2b to start 1H 2026.","Pro forma shares outstanding ~67.1M; cash expected to fund into 2027 after key data readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-090129","json":"https://secwatch.observer/filing/0001213900-25-090129.json","markdown":"https://secwatch.observer/filing/0001213900-25-090129.md","text":"https://secwatch.observer/filing/0001213900-25-090129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390025090129/0001213900-25-090129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390025090129/ea0257865-8k_oruka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:03:46.992122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e4ac9287592b8215defdd83dbcf7b87f49134e3","claim":"Oruka Therapeutics, Inc. issued 10,933,405 shares of common stock to certain institutional and accredited investors for price per share of $15.00.","evidence_excerpt":"an aggregate of 10,933,405 shares (the “Common Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price per share of $15.00","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390025090129/0001213900-25-090129-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"10,933,405 shares"},{"label":"Purchaser","value":"certain institutional and accredited investors"},{"label":"Consideration","value":"price per share of $15.00"}],"fact_type":"equity_issuance"},{"claim_id":"988255e84aaa57625a8a0fae954c37a14bfb7db6","claim":"Oruka Therapeutics, Inc. issued 1,066,666 shares of Common Stock of warrant to certain institutional and accredited investors for purchase price of $14.999 per Pre-Funded Warrant.","evidence_excerpt":"pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 1,066,666 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $14.999 per Pre-Funded Warrant","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390025090129/0001213900-25-090129-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"1,066,666 shares of Common Stock"},{"label":"Purchaser","value":"certain institutional and accredited investors"},{"label":"Consideration","value":"purchase price of $14.999 per Pre-Funded Warrant"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}